21 min listen
A Strategic Investor’s View of the Biotech Investment Landscape
FromThe Bio Report
ratings:
Length:
24 minutes
Released:
Oct 5, 2017
Format:
Podcast episode
Description
When the BIO Investor Forum convenes in San Francisco October 17 and 18, a key point of discussion will be the availability of funding for emerging life sciences companies. One of the panelist addressing that issue this year will be Asish Xavier, vice president of venture investments for Johnson & Johnson Innovation’s venture arm JJDC. We spoke to Xavier about JJDC’s approach to investing as a strategic investor, the changing landscape for venture capital, and how competitive the environment is for access to compelling technologies today.
Released:
Oct 5, 2017
Format:
Podcast episode
Titles in the series (100)
Enlisting Monoclonal Antibodies to Combat Bacterial Resistance: There’s growing global concern about threat from antibiotic resistant pathogens. That’s leading to new interest in looking beyond traditional antibiotics to monoclonal antibodies to address the problem. We spoke to Ken Stover, senior director of infe... by The Bio Report